NFKB1 and acute respiratory distress syndrome: Specifically, SCH530348 administration diminished lung PAR-1 activity, reduced thrombin expression in BALF and lung tissue, ameliorated apoptosis, and suppressed PI3K, NF-κB and MAPK signaling activation, thereby reducing proinflammatory cytokine production and subsequent ALI.